Key result
Anagliptin decreased serum FABP4 levels by 7.9% from baseline, although the difference in change compared to sitagliptin was not significant.
Why the study?
Elevated FABP4 is linked to atherosclerosis, and while sitagliptin reduces FABP4, the comparative effects of anagliptin on FABP4 remained to be investigated.
Does anagliptin reduce FABP4 concentration compared to sitagliptin in patients with type 2 diabetes mellitus at high risk for cardiovascular events receiving statin therapy?
RCT (n=307)
Open-label
Centrally done with a web-based system using an algorithm balanced for sex, body mass index, hospitals, use of DPP-4 inhibitors prior to randomization, and levels of HbA1c and LDL-C
Yes
Does anagliptin reduce FABP4 concentration compared to sitagliptin in patients with type 2 diabetes mellitus at high risk for cardiovascular events receiving statin therapy?
Anagliptin, but not sitagliptin, significantly decreases serum FABP4 concentration in high-risk patients with type 2 diabetes on statin therapy.
Answers are grounded in this paper and cite their sources.
May support FABP4 as a modifiable risk marker in T2D; leaves open whether DPP-4 effects on FABP4 improve outcomes.
BACKGROUND: Fatty acid-binding protein 4 (FABP4) acts as a novel adipokine, and elevated FABP4 concentration is associated with obesity, insulin resistance and atherosclerosis. Dipeptidyl peptidase-4 (DPP-4) inhibitors, a class of antidiabetic drugs, have distinct structures among the drugs, possibly leading to a drug class effect and each drug effect. Sitagliptin, a DPP-4 inhibitor, has been reported to decrease FABP4 concentration in drug-naïve and sulfonylurea-treated patients with type 2 diabetes mellitus. Anagliptin, another DPP-4 inhibitor, was shown to decrease low-density lipoprotein cholesterol (LDL-C) level to a greater extent than that by sitagliptin in the Randomized Evaluation of Anagliptin vs. Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. AIM AND METHODS: As a sub-analysis study using data obtained from the REASON trial, we investigated the effects of treatment with anagliptin (n = 148, male/female: 89/59) and treatment with sitagliptin (n = 159, male/female: 93/66) for 52 weeks on FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular events who were receiving statin therapy. RESULTS: The DPP-4 inhibitor had been administered in 82% of the patients in the anagliptin group and 81% of the patients in sitagliptin group prior to randomization. Serum FABP4 level was significantly decreased by 7.9% by treatment with anagliptin (P = 0.049) and was not significantly decreased by treatment with sitagliptin (P = 0.660). Change in FABP4 level was independently associated with basal FABP4 level and changes in waist circumference and creatinine after adjustment of age, sex and the treatment group. CONCLUSION: Anagliptin decreases serum FABP4 concentration independent of change in hemoglobin A1c or LDL-C in patients with type 2 diabetes mellitus and dyslipidemia who are on statin therapy. Trial registration ClinicalTrials.gov number NCT02330406. Registered January 5, 2015, https://clinicaltrials.gov/ct2/show/NCT02330406.
No takes yet. Share an insight, caveat, or question.
Furuhashi et al. (2020) conducted an RCT in Type 2 diabetes mellitus at high risk for cardiovascular events (n=307). Anagliptin vs. Sitagliptin (50 mg once daily) was evaluated on Change in serum FABP4 concentration from baseline to 52 weeks (ng/mL) (p=0.212). Anagliptin decreased serum FABP4 levels by 7.9% from baseline, although the difference in change compared to sitagliptin was not significant.
Synapse has enriched 10 related papers. Consider them for comparative context: